- Home
- VRTX vs PANW Comparison
VRTX vs PANW Comparison
Compare VRTX & PANW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRTX
- PANW
- Stock Information
- Founded
- VRTX 1989
- PANW 2005
- Country
- VRTX United States
- PANW United States
- Employees
- VRTX N/A
- PANW N/A
- Industry
- VRTX EDP Services
- PANW Computer peripheral equipment
- Sector
- VRTX Technology
- PANW Technology
- Exchange
- VRTX Nasdaq
- PANW Nasdaq
- Market Cap
- VRTX 115.6B
- PANW 124.9B
- IPO Year
- VRTX 1991
- PANW 2012
- Fundamental
- Price
- VRTX $462.13
- PANW $172.88
- Analyst Decision
- VRTX Buy
- PANW Buy
- Analyst Count
- VRTX 25
- PANW 43
- Target Price
- VRTX $509.00
- PANW $210.10
- AVG Volume (30 Days)
- VRTX 1.1M
- PANW 8.4M
- Earning Date
- VRTX 08-04-2025
- PANW 08-18-2025
- Dividend Yield
- VRTX N/A
- PANW N/A
- EPS Growth
- VRTX N/A
- PANW N/A
- EPS
- VRTX N/A
- PANW 1.74
- Revenue
- VRTX $11,099,700,000.00
- PANW $8,874,700,000.00
- Revenue This Year
- VRTX $10.43
- PANW $16.74
- Revenue Next Year
- VRTX $10.81
- PANW $13.93
- P/E Ratio
- VRTX N/A
- PANW $99.36
- Revenue Growth
- VRTX 8.98
- PANW 13.90
- 52 Week Low
- VRTX $377.85
- PANW $142.01
- 52 Week High
- VRTX $519.88
- PANW $210.39
- Technical
- Relative Strength Index (RSI)
- VRTX 49.57
- PANW 30.36
- Support Level
- VRTX $460.55
- PANW $194.77
- Resistance Level
- VRTX $474.76
- PANW $210.39
- Average True Range (ATR)
- VRTX 9.12
- PANW 6.30
- MACD
- VRTX -1.34
- PANW -2.84
- Stochastic Oscillator
- VRTX 28.52
- PANW 10.73
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
About PANW Palo Alto Networks Inc.
Palo Alto Networks is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, and security operations. The California-based firm has more than 80,000 enterprise customers across the world, including more than three fourths of the Global 2000.